全文获取类型
收费全文 | 7260篇 |
免费 | 125篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 83篇 |
妇产科学 | 79篇 |
基础医学 | 255篇 |
口腔科学 | 44篇 |
临床医学 | 583篇 |
内科学 | 3070篇 |
皮肤病学 | 275篇 |
神经病学 | 335篇 |
特种医学 | 325篇 |
外科学 | 537篇 |
综合类 | 92篇 |
预防医学 | 892篇 |
眼科学 | 420篇 |
药学 | 253篇 |
4篇 | |
中国医学 | 25篇 |
肿瘤学 | 112篇 |
出版年
2023年 | 405篇 |
2022年 | 463篇 |
2021年 | 786篇 |
2020年 | 659篇 |
2019年 | 889篇 |
2018年 | 799篇 |
2017年 | 315篇 |
2016年 | 93篇 |
2015年 | 119篇 |
2014年 | 545篇 |
2013年 | 325篇 |
2012年 | 162篇 |
2011年 | 231篇 |
2010年 | 136篇 |
2009年 | 190篇 |
2008年 | 238篇 |
2007年 | 272篇 |
2006年 | 106篇 |
2005年 | 116篇 |
2004年 | 57篇 |
2003年 | 66篇 |
2002年 | 31篇 |
2001年 | 18篇 |
2000年 | 19篇 |
1999年 | 33篇 |
1998年 | 23篇 |
1997年 | 23篇 |
1996年 | 14篇 |
1995年 | 12篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 18篇 |
1991年 | 10篇 |
1990年 | 12篇 |
1989年 | 15篇 |
1988年 | 18篇 |
1987年 | 14篇 |
1986年 | 19篇 |
1985年 | 22篇 |
1984年 | 14篇 |
1983年 | 20篇 |
1982年 | 15篇 |
1981年 | 17篇 |
1980年 | 13篇 |
1979年 | 8篇 |
1978年 | 2篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有7398条查询结果,搜索用时 15 毫秒
81.
82.
《JACC: Cardiovascular Interventions》2020,13(13):1557-1567
ObjectivesThe aim of this study was to evaluate the long-term outcomes of patients with acute coronary syndromes (ACS) with multivessel disease undergoing percutaneous coronary intervention (PCI).BackgroundControversy exists regarding the benefit of multivessel PCI across the spectrum of ACS.MethodsA total of 9,094 patients with ACS and multivessel disease (≥70% stenosis in 2 or more major epicardial vessels) undergoing PCI from the Alberta COAPT (Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies) registry (April 1, 2007, to March 31, 2013) were reviewed. Comparisons were made between patients who underwent complete revascularization and those with incomplete revascularization. Complete revascularization was defined as multivessel PCI with a residual angiographic jeopardy score ≤10%. Associations between revascularization status and all-cause death or new myocardial infarction (primary composite endpoint) and all-cause death, new myocardial infarction, or repeat revascularization (secondary composite endpoint) were evaluated.ResultsOf the study cohort, 66.0% underwent complete revascularization. Compared with incomplete revascularization, the primary composite endpoint occurred less frequently with complete revascularization (event rate within 5 years 15.4% vs. 22.2%; inverse probability-weighted hazard ratio [IPW-HR]: 0.78; 95% confidence interval [CI]: 0.73 to 0.84; p < 0.0001). The secondary composite endpoint was less likely to occur with complete revascularization (event rate within 5 years 23.3% vs. 37.5%; IPW-HR: 0.61; 95% CI: 0.58 to 0.65; p < 0.0001). Complete revascularization was associated with a reduction in all-cause death (IPW-HR: 0.79; 95% CI: 0.73 to 0.86; p = 0.0004), new myocardial infarction (IPW-HR: 0.76; 95% CI: 0.69 to 0.84; p < 0.0001), and repeat revascularization (IPW-HR: 0.53; 95% CI: 0.49 to 0.57; p < 0.0001).ConclusionsResults from this large contemporary registry of patients with ACS and PCI for multivessel disease suggest that complete revascularization occurs commonly and is associated with improved clinical outcomes (including survival) within 5 years. 相似文献
83.
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis 总被引:10,自引:0,他引:10
BACKGROUND AND AIMS: The evidence that proton pump inhibitor (PPI) therapy affects symptoms of nonulcer dyspepsia is conflicting. We conducted a systematic review to evaluate whether PPI therapy had any effect in nonulcer dyspepsia and constructed a health economic model to assess the cost-effectiveness of this approach. METHODS: Electronic searches were performed using the Cochrane Controlled Trials Register, MEDLINE, EMBASE, CINAHL, and SIGLE until September 2002. Dyspepsia outcomes were dichotomized into cured/improved versus same/worse. Results were incorporated into a Markov model comparing health service costs and benefits of PPI with antacid therapy over 1 year. RESULTS: Eight trials were identified that compared PPI therapy with placebo in 3293 patients. The relative risk of remaining dyspeptic with PPI therapy versus placebo was .86 (95% confidence interval, .78-.95; P = .003, random-effects model) with a number needed to treat of 9 (95% confidence interval, 5-25). There was statistically significant heterogeneity between trials (heterogeneity chi(2) = 30.05; df = 7; P < .001). The PPI strategy would cost an extra US dollar 278/month free from dyspepsia if the drug cost US dollar 90/month. If a generic price of US dollar 19.99 is used, then a PPI strategy costs an extra US dollar 57/month free from dyspepsia. A third-party payer would be 95% certain that PPI therapy would be cost-effective, provided they were willing to pay US dollar 94/month free from dyspepsia. CONCLUSIONS: PPI therapy may be a cost-effective therapy in nonulcer dyspepsia, provided generic prices are used. 相似文献
84.
85.
86.
87.
F.V. Cureau K. Sparrenberger K.V. Bloch U. Ekelund B.D. Schaan 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2018,28(7):765-774
Background and Aims
Physical inactivity, unhealthy diet, smoking and heavy drinking are four key unhealthy lifestyle behaviors (ULB) that may influence body weight and obesity development. More recently, sedentary time has been recognized as another potentially emerging ULB related to obesity. We therefore investigated the association of multiple ULB with overweight/obesity and abdominal obesity among Brazilian adolescents.Methods and Results
This cross-sectional study involved 62,063 students (12–17 years). Physical inactivity, high screen time, low fiber intake, binge drinking and smoking were self-reported and combined to a ULB risk score, ranging from zero to five. Participants were classified as overweight/obese or with abdominal obesity using sex and age-specific cut-off points for BMI and waist circumference, respectively. Poisson regression models were used to examine the associations between ULB with overweight/obesity and abdominal obesity, adjusted for socio-demographic variables. Overall, 2.3%, 18.9%, 43.9%, 32.3% and 2.6% of participants reported zero, one, two, three and four/five ULB, respectively. Higher ULB risk score was associated with overweight/obesity and abdominal obesity in a dose–response gradient. Among 32 possible combinations of ULB, the three most prevalent combinations (physical inactivity + low fiber intake; high screen time + low fiber intake; physical inactivity + high screen time + low fiber intake) were positively associated with general and abdominal obesity.Conclusions
Our findings suggest a synergistic relationship between ULB and general and abdominal obesity. Preventive efforts targeting combined ULB should be sought to reduce the prevalence of general and abdominal obesity in Brazilian youth. 相似文献88.
89.
The association between hepatitis C infection and survival after orthotopic liver transplantation 总被引:36,自引:0,他引:36
BACKGROUND & AIMS: The effect of hepatitis C viral (HCV) infection on patient and allograft survival after orthotopic liver transplantation is controversial. Hepatitis C recurrence after transplant is inevitable, but studies to date have not found a survival difference between recipients with and without HCV. METHODS: Using data from the United Network for Organ Sharing, we performed a retrospective cohort study of 11,036 patients who underwent 11,791 liver transplants between 1992 and 1998. The hazard rates of patient and allograft survival for patients who were HCV-positive as compared with patients who were HCV-negative were assessed by proportional-hazards analysis, with adjustment for potential confounding variables, including donor, recipient, and transplant center characteristics. RESULTS: Liver transplantation in HCV-positive recipients was associated with an increased rate of death (hazard ratio, 1.23; 95% confidence interval [CI], 1.12-1.35) and allograft failure (hazard ratio, 1.30; 95% CI, 1.21-1.39), as compared with transplantation in HCV-negative recipients. This reduction in survival persisted after adjusting for potential confounders. There was an interaction between HCV and sex (P < 0.001) with the effect of HCV on survival being most pronounced in female recipients (patient survival hazard ratio, 1.56; 95% CI, 1.35-1.81; allograft survival hazard ratio, 1.51; 95% CI, 1.34-1.70). CONCLUSIONS: HCV infection significantly impairs patient and allograft survival after liver transplantation. 相似文献